EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 17 Issue 2
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

Idorsia scores FDA go-ahead for insomnia drug Quviviq to rival Merck’s Belsomra, Eisai’s Dayvigo

The FDA blessed Idorsia's Quviviq (daridorexant), a sleeping pill for those with insomnia. Because the FDA has recommended Idorsia to register Quviviq as a controlled...
11 January 2022 Regional News diagnosed | FDA
Continue Reading →
Regional News

Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe

Despite classwide safety worries in the U.S., AbbVie is making strides in its quest to build immunology up-and-comer Rinvoq. AbbVie sent off applications to U.S. and...
11 January 2022 Regional News AbbVie | drug
Continue Reading →
Regional News

Antares Pharma develops novel auto-injector devices for innovative combination products

With over 30 years of experience in drug device engineering, Antares Pharma has nurtured its R&D prowess and specialized in creating custom designed drug delivery...
11 January 2022 Regional News Antares | auto-injector
Continue Reading →
Regional News

JPM 2022: Vertex’s Trikafta holds the line as company lays groundwork for gene editing launch

Vertex Pharmaceuticals is well known for its slew of cystic fibrosis medications, and newcomer Trikafta is pulling its weight. Over the course of 2021, the med clinch...
11 January 2022 Regional News company | fibrosis
Continue Reading →
Regional News

ASH: Astellas looks for silver linings in failed Xospata combo trial

Eying growth in oncology, Astellas has suffered an R&D setback for acute myeloid leukemia drug Xospata (gilteritinib). The med flunked a combo trial with Bristol ...
15 December 2021 Regional News acute myeloid leukemia | Astellas
Continue Reading →
Regional News

Bayer targets 100% green packaging for consumer health brands by 2030 as part of €100 million sustainability plan

Eying growth in oncology, Astellas has suffered an R&D setback for acute myeloid leukemia drug Xospata (gilteritinib). The med flunked a combo trial with Bristol ...
15 December 2021 Regional News acute myeloid leukemia | Astellas
Continue Reading →
Regional News

ASH: Roche’s Polivy set to unlock $2B market in newly diagnosed lymphoma with practice-changing data

The guessing is over. Roche has detailed new Polivy data that could change nearly two decades of treatment standards in newly diagnosed lymphoma—while opening up a bl...
15 December 2021 Regional News antibody drug conjugates | ASH 2021
Continue Reading →
Regional News

ASH: Novartis thinks it knows why Kymriah failed in earlier lymphoma but shifts focus to next-gen CAR-T meds

Kymriah’s shocking failure in earlier lymphoma treatment has raised doubts about the Novartis drug’s potency in light of impressive victories from rival CAR-Ts by Gil...
15 December 2021 Regional News ASH 2021 | Breyanzi
Continue Reading →
Regional News

CSL to buy Vifor for $11.7B in biopharma’s largest M&A deal this year

In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent on vacci...
15 December 2021 Regional News a CSL Behring | Fresenius
Continue Reading →
Regional News

AstraZeneca and other lung cancer specialists join together to emphasize early screenings

If there is one strong message Camille Hertzka, AstraZeneca vice president and head of oncology, U.S. medical, wants people to take away from lung cancer awareness su...
15 December 2021 Regional News AstraZeneca | Guardant Health
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2025, All Rights Reserved – Powered by Teksyte